Dissecting Innate and Adaptive Immunity in Inflammatory Bowel Disease: Immune Compartmentalization, Microbiota Crosstalk, and Emerging Therapies
Ningning Yue,Peng Hu,Chengmei Tian,Chen Kong,Hailan Zhao,Yuan Zhang,Jun Yao,Yuqi Wei,Defeng Li,Lisheng Wang
DOI: https://doi.org/10.2147/jir.s492079
IF: 4.5
2024-11-29
Journal of Inflammation Research
Abstract:Ningning Yue, 1, &ast Peng Hu, 2, &ast Chengmei Tian, 3 Chen Kong, 1 Hailan Zhao, 1 Yuan Zhang, 4 Jun Yao, 1 Yuqi Wei, 5 Defeng Li, 1 Lisheng Wang 1 1 Department of Gastroenterology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, People's Republic of China; 2 School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, People's Republic of China; 3 Department of Emergency, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, People's Republic of China; 4 Department of Medical Administration, Huizhou Institute of Occupational Diseases Control and Prevention, Huizhou, People's Republic of China; 5 Department of Rehabilitation, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, People's Republic of China &astThese authors contributed equally to this work Correspondence: Defeng Li; Lisheng Wang, Department of Gastroenterology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; the First Affiliated Hospital, Southern University of Science and Technology), No.1017, Dongmen North Road, Luohu District, Shenzhen, 518020, People's Republic of China, Tel +86 755 25533018, Email ; The intestinal immune system is the largest immune organ in the human body. Excessive immune response to intestinal cavity induced by harmful stimuli including pathogens, foreign substances and food antigens is an important cause of inflammatory diseases such as celiac disease and inflammatory bowel disease (IBD). Although great progress has been made in the treatment of IBD by some immune-related biotherapeutic products, yet a considerable proportion of IBD patients remain unresponsive or immune tolerant to immunotherapeutic strategy. Therefore, it is necessary to further understand the mechanism of immune cell populations involved in enteritis, including dendritic cells, macrophages and natural lymphocytes, in the steady-state immune tolerance of IBD, in order to find effective IBD therapy. In this review, we discussed the important role of innate and adaptive immunity in the development of IBD. And the relationship between intestinal immune system disorders and microflora crosstalk were also presented. We also focus on the new findings in the field of T cell immunity, which might identify novel cytokines, chemokines or anti-cytokine antibodies as new approaches for the treatment of IBD. Keywords: ulcerative colitis, Crohn's disease, inflammatory bowel disease, immunology, therapy Graphical Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic relapsing inflammatory disorder of the gastrointestinal (GI) tract. The condition is characterized pathologically by intestinal inflammation and epithelial damage. 1 Notably, the prevalence of IBD exceeds 0.3% in Western nations and is progressively rising in newly industrialized countries with their increasingly Westernized societies. 2 UC primarily involves the rectum, affecting part of the colon or the entire colon in an inverted continuous pattern. In contrast, CD typically affects the ileum and colon, with intermittent involvement of other GI tract regions. The predominant clinical symptoms for IBD include recurrent abdominal pain, diarrhea, and rectal bleeding. In certain cases, extraintestinal manifestations such as uveitis, erythema nodosum, and primary sclerosing cholangitis can also occur in conjunction with the aforementioned symptoms. 3,4 IBD necessitates lifelong management to prevent disease deterioration, along with close collaboration between general practitioners and specialists. Currently, the medical interventions utilized for IBD patients primarily consist of 5-aminosalicylates, glucocorticoids, immunosuppressive agents, and biologics. 5 Although favorable therapeutic effects of these drugs are observed in certain patients, long-term outcomes for many remain suboptimal. Additionally, they are often associated with significant adverse effects, including increased risk of infection, drug tolerance, and other immune-related complications. 6 The precise mechanisms underlying the pathogenesis of IBD remain elusive; however, an increasing body of evidence suggests that IBD is the result of an inappropriate immune response to intestinal mi -Abstract Truncated-
immunology